• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新诊断多发性骨髓瘤临床实验室指标的最佳截断值及诊断意义

Optimal cut-off values and diagnostic significance of clinical laboratory indicators in newly diagnosed multiple myeloma.

作者信息

Li Manning, Wu Han, Shou Chunyi, Peng Ye, Song Xiaolu, Ying Wang, Chen Yirui, Tong Xiangmin

机构信息

Graduate School of Clinical Medicine, Jinzhou Medical University, 40 Songpo Road, Jinzhou, 121001, Liaoning, China.

Cancer Center, Department of Hematology, Affiliated People's Hospital, Zhejiang Provincial People's Hospital, Hangzhou Medical College, 158 Shangtang Road, Hangzhou, 310014, Zhejiang, People's Republic of China.

出版信息

Discov Oncol. 2024 Sep 27;15(1):477. doi: 10.1007/s12672-024-01254-z.

DOI:10.1007/s12672-024-01254-z
PMID:39331239
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11436520/
Abstract

OBJECTIVE

This study aims to identify clinical laboratory parameters for the diagnosis of newly diagnosed multiple myeloma (NDMM), establish optimal cutoffs for early screening, and develop a diagnostic model for precise diagnosis.

METHODS

The study conducted a retrospective analysis of 279 NDMM patients and 553 healthy subjects at Zhejiang Province People's Hospital between January 2008 and June 2023. Multifactor LR was employed to explore clinical laboratory indicators with diagnostic value for NDMM, determine optimal cutoff values and contract a diagnostic model. The diagnostic efficacy and clinical utility were evaluated using receiver operating characteristic curves (ROC), sensitivity, specificity, and other indicators.

RESULTS

Multifactor analysis revealed that hemoglobin (Hb), albumin (Alb), and platelet distribution width (PDW) were significant diagnostic factors for NDMM. Optimal cutoff values for Hb, Alb, and PDW in MM diagnosis were determined, and the results showed a significant increase in the probability of NDMM diagnosis when Alb was below 39.3 g/L, Hb was below 11.6 g/dL, and PDW was below 14.1 fL. The diagnostic model constructed from the development cohort demonstrated a high area under the ROC curve of 0.960 (95% CI 0.942-0.978) and exhibited good sensitivity (0.860), specificity (0.957). The area under the curve (AUC) value of the diagnostic model in the external validation cohort was 0.979, confirming its good diagnostic efficacy and generalization.

CONCLUSIONS

The optimal cutoff values for Hb, Alb, and PDW and the diagnostic model designed in the study provided good accuracy and sensitivity for the initial screening and diagnosis of NDMM.

摘要

目的

本研究旨在确定新诊断多发性骨髓瘤(NDMM)的临床实验室参数,建立早期筛查的最佳临界值,并开发精确诊断的诊断模型。

方法

本研究对2008年1月至2023年6月期间浙江省人民医院的279例NDMM患者和553例健康受试者进行了回顾性分析。采用多因素逻辑回归(LR)探索对NDMM具有诊断价值的临床实验室指标,确定最佳临界值并构建诊断模型。使用受试者工作特征曲线(ROC)、敏感性、特异性等指标评估诊断效能和临床实用性。

结果

多因素分析显示,血红蛋白(Hb)、白蛋白(Alb)和血小板分布宽度(PDW)是NDMM的重要诊断因素。确定了MM诊断中Hb、Alb和PDW的最佳临界值,结果显示,当Alb低于39.3 g/L、Hb低于11.6 g/dL且PDW低于14.1 fL时,NDMM诊断概率显著增加。从开发队列构建的诊断模型在ROC曲线下面积较高,为0.960(95%CI 0.942-0.978),敏感性良好(0.860),特异性良好(0.957)。外部验证队列中诊断模型的曲线下面积(AUC)值为0.979,证实了其良好的诊断效能和泛化能力。

结论

本研究设计的Hb、Alb和PDW最佳临界值及诊断模型为NDMM的初步筛查和诊断提供了良好的准确性和敏感性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ced/11436520/17246308200c/12672_2024_1254_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ced/11436520/9fea02176d01/12672_2024_1254_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ced/11436520/945681713cfa/12672_2024_1254_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ced/11436520/17246308200c/12672_2024_1254_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ced/11436520/9fea02176d01/12672_2024_1254_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ced/11436520/945681713cfa/12672_2024_1254_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ced/11436520/17246308200c/12672_2024_1254_Fig3_HTML.jpg

相似文献

1
Optimal cut-off values and diagnostic significance of clinical laboratory indicators in newly diagnosed multiple myeloma.新诊断多发性骨髓瘤临床实验室指标的最佳截断值及诊断意义
Discov Oncol. 2024 Sep 27;15(1):477. doi: 10.1007/s12672-024-01254-z.
2
[Clinical Significance of Serum ADA Combined with GLB, CREA, β-MG and HGB in Newly Diagnosed Multiple Myeloma].血清ADA联合GLB、CREA、β-MG及HGB在新诊断多发性骨髓瘤中的临床意义
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2024 Jun;32(3):780-788. doi: 10.19746/j.cnki.issn.1009-2137.2024.03.019.
3
Significance of Common Blood Test Indexes in the Diagnosis and Prognosis of Multiple Myeloma.常见血液检测指标在多发性骨髓瘤诊断和预后中的意义。
Clin Lab. 2022 Apr 1;68(4). doi: 10.7754/Clin.Lab.2021.210716.
4
[Analysis of the diagnostic efficiency of combining multiple laboratory hematological indicators in alpha-fetoprotein-negative hepatocellular carcinoma].[多种实验室血液学指标联合诊断甲胎蛋白阴性肝细胞癌的效能分析]
Zhonghua Yi Xue Za Zhi. 2022 May 10;102(17):1303-1310. doi: 10.3760/cma.j.cn112137-20220115-00103.
5
Establishment of Multiple Myeloma Diagnostic Model Based on Logistic Regression in Clinical Laboratory.基于临床检验中逻辑回归的多发性骨髓瘤诊断模型的建立
Clin Lab. 2020 Aug 1;66(8). doi: 10.7754/Clin.Lab.2019.190832.
6
Prognostic value of semi-quantitative parameters of F-FDG PET/CT in newly diagnosed multiple myeloma patients.初诊多发性骨髓瘤患者 F-FDG PET/CT 半定量参数的预后价值。
Ann Nucl Med. 2023 Mar;37(3):155-165. doi: 10.1007/s12149-022-01812-x. Epub 2022 Dec 17.
7
[Change of platelet parameters in septic shock patients].[脓毒症休克患者血小板参数的变化]
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2014 Jan;26(1):28-32. doi: 10.3760/cma.j.issn.2095-4352.2014.01.006.
8
[Analysis of the clinical characteristics of severe tsutsugamushi disease in Yunnan Province from 2017 to 2018].[2017至2018年云南省恙虫病重症临床特征分析]
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2019 Aug;31(8):1018-1023. doi: 10.3760/cma.j.issn.2095-4352.2019.08.021.
9
Construction and validation of an F-FDG-PET/CT-based prognostic model to predict progression-free survival in newly diagnosed multiple myeloma patients.构建并验证基于 F-FDG-PET/CT 的预测初诊多发性骨髓瘤患者无进展生存期的预后模型。
Hematology. 2024 Dec;29(1):2329029. doi: 10.1080/16078454.2024.2329029. Epub 2024 Mar 15.
10
[Predictive Value of Pre-treatment Serum Uric Acid Level for Prognosis in Newly Diagnosed Patients with Multiple Myeloma].[治疗前血清尿酸水平对新诊断多发性骨髓瘤患者预后的预测价值]
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2021 Aug;29(4):1216-1223. doi: 10.19746/j.cnki.issn.1009-2137.2021.04.030.

引用本文的文献

1
Predictors and Profile of Severe Infectious Complications in Multiple Myeloma Patients Treated with Daratumumab-Based Regimens: A Machine Learning Model for Pneumonia Risk.接受基于达雷妥尤单抗方案治疗的多发性骨髓瘤患者严重感染并发症的预测因素及特征:肺炎风险的机器学习模型
Cancers (Basel). 2024 Nov 3;16(21):3709. doi: 10.3390/cancers16213709.

本文引用的文献

1
The value of serum albumin concentration in predicting functional outcome of status epilepticus: An observational study.血清白蛋白浓度在预测癫痫持续状态功能结局中的价值:一项观察性研究。
Epileptic Disord. 2023 Apr;25(2):150-159. doi: 10.1002/epd2.20001. Epub 2023 Apr 29.
2
Management of Multiple Myeloma: A Review for General Practitioners in Oncology.多发性骨髓瘤的治疗:肿瘤学全科医生的综述。
Curr Oncol. 2023 Apr 22;30(5):4382-4401. doi: 10.3390/curroncol30050334.
3
The level of serum albumin is associated with renal prognosis and renal function decline in patients with chronic kidney disease.
血清白蛋白水平与慢性肾脏病患者的肾脏预后和肾功能下降有关。
BMC Nephrol. 2023 Mar 15;24(1):57. doi: 10.1186/s12882-023-03110-8.
4
The effect of haemoglobin, albumin, lymphocyte and platelet score on the prognosis in patients with multiple myeloma.血红蛋白、白蛋白、淋巴细胞和血小板评分对多发性骨髓瘤患者预后的影响。
Int J Lab Hematol. 2023 Feb;45(1):13-19. doi: 10.1111/ijlh.13958. Epub 2022 Sep 2.
5
Is RDW a clinically relevant prognostic factor for newly diagnosed multiple myeloma? A systematic review and meta-analysis.RDW 是否是新诊断多发性骨髓瘤的临床相关预后因素?系统评价和荟萃分析。
BMC Cancer. 2022 Jul 19;22(1):796. doi: 10.1186/s12885-022-09902-9.
6
Mean platelet volume (MPV) and platelet distribution width (PDW) predict clinical outcome of acute ischemic stroke: A systematic review and meta-analysis.平均血小板体积 (MPV) 和血小板分布宽度 (PDW) 预测急性缺血性脑卒中的临床转归:系统评价和荟萃分析。
J Clin Neurosci. 2022 Jul;101:221-227. doi: 10.1016/j.jocn.2022.05.019. Epub 2022 May 26.
7
Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project.修订版国际分期系统(R2-ISS)在多发性骨髓瘤整体生存中的应用:Harmony 项目下欧洲骨髓瘤网络(EMN)的报告。
J Clin Oncol. 2022 Oct 10;40(29):3406-3418. doi: 10.1200/JCO.21.02614. Epub 2022 May 23.
8
Significance of Common Blood Test Indexes in the Diagnosis and Prognosis of Multiple Myeloma.常见血液检测指标在多发性骨髓瘤诊断和预后中的意义。
Clin Lab. 2022 Apr 1;68(4). doi: 10.7754/Clin.Lab.2021.210716.
9
Diagnosis and Management of Multiple Myeloma: A Review.多发性骨髓瘤的诊断与治疗:综述
JAMA. 2022 Feb 1;327(5):464-477. doi: 10.1001/jama.2022.0003.
10
Cancer statistics, 2022.癌症统计数据,2022 年。
CA Cancer J Clin. 2022 Jan;72(1):7-33. doi: 10.3322/caac.21708. Epub 2022 Jan 12.